Following her earlier analysis of the shortcomings of adverse event data in medicinal cannabis, Dr Teresa Nicoletti contends that the Therapeutic Goods Administration's (TGA) latest discussion paper may signal a broader regulatory reset targeting high-THC products and inhaled cannabis forms.
The TGA recently submitted a "discussion paper" to the Advisory Committee on Medicines Scheduling (ACMS) outlining the findings from its consultation on the safety and regulatory oversight of unapproved medicinal cannabis products, along with the following attachments:
- Attachment A: Scheduling of cannabis, cannabidiol and tetrahydrocannabinol.
- Attachment B: Scheduling history of cannabis, cannabidiol and tetrahydrocannabinol.
- Attachment C: Consultation Paper: Reviewing the safety and regulatory oversight of unapproved medicinal cannabis products.
The discussion paper and its attachments were released on April 10 pursuant to a Freedom of Information (FOI) request but have not yet appeared in the TGA's FOI disclosure log.
At first reading, the discussion paper appears to be a technical and historical background document.
When considered alongside the attachments, however, it discloses something more significant: a regulator systematically laying the groundwork to reclaim orthodox pharmacological control over medicinal cannabis — particularly high-THC products and inhaled forms — after nearly a decade of access that has grown at an unexpectedly rapid pace.
“After ten years of legalisation, this regulatory posturing cannot be described as a reactionary crackdown but, rather, a recalibration that has long been in the making, and it is being framed with care.”
Medicinal cannabis access in Australia expanded rapidly after 2016, following the creation of Schedule 8 entries for cannabis and THC and enabled by unapproved pathways such as the Special Access Scheme (SAS) and Authorised Prescriber Scheme (APS). These frameworks were conceived as exceptions — practical tools to allow access where conventional registered medicines were unavailable.
Yet, as the TGA now candidly acknowledges, what was intended to be narrow, conditional access has evolved into a large, commercialised marketplace characterised by:
• high-potency THC products;
• widespread use of inhaled dosage forms;
• broad prescribing across indications with limited clinical evidence; and
• minimal product-specific safety data.
This drift is the central concern underpinning the regulator's current posture.
The consultation summary makes this plain. Stakeholders repeatedly raised alarms about psychosis, cannabis use disorder, vulnerable populations, inhalation routes and the absence of enforceable THC limits.
These concerns did not originate solely from external critics; they came from consumers, clinicians, governments and peak bodies alike. The TGA is signalling that the social licence supporting the current framework is eroding.
Attachment B to the discussion paper could be read as a neutral history of scheduling decisions, but in our view it amounts to something more — closer to a legal and policy brief, reminding those to whom it is directed, and perhaps future critics, of several material facts:
• Cannabis and tetrahydrocannabinol (THC) were placed under strict controls because of abuse potential and international treaty obligations, not moral panic.
• Every subsequent relaxation was deliberately narrow, product-specific and indication-specific.
• Cannabidiol's (CBD's) relative tolerance was hard-fought and still conditional, with regulators repeatedly rejecting general sale on the grounds that uncertainty equals risk.
The message is subtle but unmistakable: current regulatory practice has drifted beyond its original intent. By anchoring today's debate in decades of consistent scheduling logic, the TGA is insulating itself against claims of overreach. The TGA is reasserting first principles to an industry that has changed rapidly; the regulatory philosophy itself has not shifted.
Across the Discussion Paper, one substance sits unmistakably at the centre of concern:
• The consultation revealed significant unease with the concentration of THC now accessible through unapproved products, particularly when delivered via inhalation.
• That concern is not merely clinical; it is structural. Unlike CBD, THC engages psychoactively; poses dependence risk; has well-established links to psychosis in susceptible individuals; and is subject to international drug control frameworks.
The TGA therefore appears to be preparing the case for THC exceptionalism — the proposition that THC must be regulated differently within the medicinal cannabis framework.
That logic points naturally toward reforms such as:
• THC concentration caps that vary by dosage form;
• stricter controls (or possibly outright discouragement) of inhaled routes; and
• enhanced prescriber gatekeeping for high-THC products.
Crucially, these measures do not require the TGA to demonstrate a new safety signal. The TGA is well aware that no formal signal has been identified, but is equally clear that this does not preclude reform. Precaution, consistency and alignment with scheduling principles are presented as sufficient justification.
Perhaps the most consequential shift concerns how unapproved medicinal cannabis products are now framed. Where unapproved access was once described as a compassionate and necessary bridge, it is increasingly characterised as an inherently limited, evidence-poor environment that constrains the TGA's ability to assess risk, efficacy or benefit.
The TGA acknowledges that a formal, conclusive safety report on medicinal cannabis is constrained by a lack of baseline data and under-reporting of adverse events — but this will not exonerate the sector. This raises a key issue: the absence of evidence of harm does not equate to evidence of safety.
This matters because it frames reform as an obligation rather than a choice. If risks cannot be properly characterised under unapproved pathways, sustaining large-scale, long-term access through those pathways becomes increasingly untenable.
On the whole, the Discussion Paper points toward a trajectory that will:
• re-contain THC, particularly high-potency THC products and inhaled THC-containing products.
• impose stronger prescriber obligations, potentially including specialist-only prescribing for certain products or populations.
• require tighter packaging, labelling and patient warnings — not as consumer education, but as harm-minimisation tools.
• increase pressure to transition toward ARTG-registered products, with unapproved pathways framed as temporary and exceptional.
We read the present manoeuvres as regulatory discipline reasserting itself after a period of exceptionalism — during which controls on the supply of medicinal cannabis have been more lenient relative to other medicines — rather than as prohibition by stealth.
The medicinal cannabis sector should not treat the current consultation as routine or as business as usual. The TGA is doing what it always does before difficult reform: assembling history, consensus and principle into a defensible narrative.
Anyone who assumes that the current access environment will remain unchanged is misreading the signals. That is not to say the window is slamming shut, but it is narrowing — and that narrowing is intentional.
The question for industry, clinicians and investors is not whether reform is coming, but whether their business models have the resilience to pivot if controls are imposed on THC that position it more like the exceptional substance it was before medicinal cannabis was legalised.
